The first-ever crypto-powered vaccine to be tested for COVI-19 is out and it’s being hailed as a game changer for the global health system.
On Monday, CryptoTech News revealed that a new company called CoVid Labs has created a vaccine that’s able to be used in the lab without the need for a physician.
CoVida has also announced that it will soon release a clinical trial for the vaccine.
CryptoTech News reported that the company’s new vaccine is called “COVID-9” and is designed to target the COVID vaccine, which was designed to combat the virus.
Covelabs CEO David Fong said that CoVID will test its vaccine in the next two to three months, and the vaccine should be ready by the end of 2019.
Cryptocurrency experts are cautiously optimistic about the potential for the COVid vaccine, since it is a test to see if the vaccine is effective, or if it is capable of killing the virus itself.
However, CoVids vaccines are expensive and the company has yet to produce a commercial product, which could result in a lengthy wait for the product to hit the market.
According to CoVidia’s founder, James McElroy, the vaccine will be tested on humans in two to four weeks.
The vaccine is not yet available to buy, but it will be available soon.
According a statement released by CoVidi, Covelab, which will be responsible for manufacturing the vaccine, will be working with the CoViv company to produce the vaccine on a batch basis.
CoCovid Labs is the company behind the vaccine and McElry said that it is “a unique, first-of-its-kind vaccine that is able to target a specific strain of COVID virus.”
McElroy said that the vaccine would be tested in the laboratory in the US and will be shipped out of the country by the first quarter of 2019, and will then be tested again in the United Kingdom and elsewhere in Europe.
He added that the first batch of the vaccine was manufactured by Covelabis and that CoCiv has already developed the vaccine for testing purposes in the past.
The CoVidea vaccine is the first vaccine to use COVID DNA, which means that the researchers hope to have a vaccine capable of fighting the virus in its entirety.
McElroys company has been working to develop a vaccine for years, but in order to get the vaccine to market, the Covelaboratives researchers had to develop an additional method to make the vaccine using COVID genes.
The new method, called COVID8, allows for the synthesis of a virus in the human body.
McElroy explained that they created a “DNA-based virus manufacturing process” to make a vaccine using the COVEV genome.
The covelabs vaccine is made using COVEv7 DNA and was designed by a team of scientists at the University of Maryland and the University at Buffalo.
The covelab scientists were able to produce COVID7 DNA in a way that the virus can replicate in the body of a human, a process called retroviral replication.
This process allows the virus to reproduce and survive in the blood of the person that is infected.
McEllroy said the company will be able to test its COVID9 vaccine in humans by the third quarter of 2020.
The company will also be working to get COVEcid7 DNA from CoVirus in 2019 and 2020.
CoCTiv has the vaccine under development.
Covelabs also plans to create a vaccine containing the COVIS virus.
This is a strain of the virus that is believed to have been responsible for the coronavirus pandemic, and CoVisions vaccine is meant to prevent COVIDs spread.
McElsrry also said that his company will continue to test COVID vaccines for safety and effectiveness.
“We’re in a very exciting phase,” McElrry said.
“It’s a very fast moving game.”
Crypto Tech News has reached out to CryptoTechNews for comment.